Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Air T, Inc. reported financial results for its second fiscal quarter ended September 30, 2026, with revenue increasing 129% to $146.9 million, primarily driven by the acquisition of Regional Express Holdings (Rex). The company reported a net loss of $7.48 per share, impacted by operational challenges at Rex including unscheduled engine removals and high fuel costs.
Term
Q2 2027
“While focused in one sector and with some interdependencies, Air T can be viewed as a set of businesses that operate independently of one another. The quarter just passed is an example of widely variable operational dynamics across our businesses.”
Nick Swenson, Company Chairman and CEO
“Rex financial performance was notably challenged in the quarter due to a combination of unscheduled engine removals, delays at engine overhaul shops and a doubling of fuel costs compared to pre-war levels.”
Calidi Biotherapeutics reported a net loss of $3.6 million for the third quarter of 2026, a significant improvement from the $10.8 million loss in the prior year period. The company highlighted preclinical progress for its CLD-401 program and implemented a restructuring plan on November 6, 2026, to reduce headcount and save $3 million annually. During the quarter, the company also raised $1.2 million through an at-the-market offering to extend its cash runway.
Term
Q3 2026
“Throughout the third quarter, Calidi continued to advance its RedTail platform for systemic and local delivery and redefine the potential of oncolytic viruses and genetic medicine. In particular, CLD-401 demonstrated remarkable anti-tumor activity with systemic administration in syngeneic tumor models and continues to progress towards the clinic.”
WTI Fund X, Inc. reported a net increase in net assets resulting from operations of $26.2 million for the nine months ended September 30, 2026, down slightly from $27.6 million in the prior year period. The company significantly reduced its debt facility borrowings from $232.5 million at year-end 2025 to $95.0 million, while net assets increased to $209.2 million.
ADM Endeavors, Inc. reported total revenue of $4.58 million for the nine months ended September 30, 2026, a slight increase from $4.31 million in the prior year period. The company achieved a net income of $127,075 for the first nine months of 2026, down from $250,321 in 2025, primarily due to significantly higher interest expenses and the absence of a large gain on an insurance claim seen in the previous year.
Forbright, Inc. filed its 10-Q for the period ending September 30, 2026, reporting 33,601,078 shares of Class A common stock outstanding. The filing highlights a pending branch sale agreement and the adoption of the 2026 Omnibus Incentive Plan, while emphasizing risks related to AI implementation and credit quality.
Churchill Capital Corp XI (CCXI) completed its business combination with Legacy Agility on November 2, 2026, subsequently changing its name to Agility Robotics, Inc. The filing covers the period ended September 30, 2026, prior to the merger's consummation, and reflects a pre-money equity value for Legacy Agility of $2.5 billion.
NexPoint Diversified Real Estate Trust reported total assets of $993.4 million as of September 30, 2026, a decrease from $1.07 billion at year-end 2025. The company experienced a significant increase in its accumulated loss to $458.2 million, while total shareholders' equity declined from $700.1 million to $610.6 million during the nine-month period.
Broadway Financial Corp reported net income of $1.1 million for the third quarter of 2026, a significant recovery from a $23.9 million loss in the prior year period which was driven by a $25.9 million goodwill impairment. Total assets grew to $1.56 billion as of September 30, 2026, primarily fueled by a $192.4 million increase in deposits and growth in the loan portfolio.
Air T Inc. reported a significant increase in operating revenues to $262.4 million for the six months ended September 30, 2026, driven by the addition of regional airline and aviation leasing segments. However, the company swung to a net loss of $35.2 million compared to a profit in the prior year, primarily due to higher operating expenses, increased interest costs, and a $3.4 million earnout remeasurement charge.
KPET Ultra Paceline Corp reported net income of $3.53 million for the nine months ended September 30, 2026, primarily driven by $4.08 million in interest earned on investments held in the Trust Account. As a shell company, its primary assets consist of $233.8 million in the Trust Account, while it maintains a shareholders' deficit of $11.23 million due to the accretion of Class A ordinary shares to redemption value.
Golden Minerals Company reported a net loss of $0.7 million for the nine months ended September 30, 2026, an improvement from a $3.0 million loss in the prior year period, primarily due to $1.1 million in income from discontinued operations. The company remains in the exploration stage with no mineral reserves, maintaining a cash balance of $1.7 million as of the end of the third quarter.
Moleculin Biotech reported a net loss of $27.0 million for the nine months ended September 30, 2026, compared to a $49.1 million loss in the prior year period. The company ended the quarter with $7.3 million in cash and cash equivalents, supported by $20.3 million in net cash provided by financing activities during the year.
For the nine months ended September 30, 2026, Silo Pharma reported a net loss of $2.84 million, an improvement from the $3.35 million loss in the prior year period. The company's cash position increased to $6.09 million, bolstered by a $0.70 million gain from the termination of a sublicense agreement and financing activities.
RMG ML Sports Holdings reported a net loss of $4.30 million for the nine months ended September 30, 2026, primarily driven by $6.79 million in general and administrative expenses. As a shell company, its assets are largely comprised of $218.92 million held in a Trust Account following its initial public offering in mid-2026.
For the nine months ended September 30, 2026, Graf Global Corp. reported net income of $1,588,180, driven by $5,076,172 in interest earned on trust account funds. The company experienced significant redemptions during the period, with $158,489,876 withdrawn from the Trust Account to redeem Class A ordinary shares.
CirTran Corporation reported a significant turnaround for the nine months ended September 30, 2026, with net income of $1,827,615 compared to a net loss of $1,138,064 in the prior year, primarily driven by income from discontinued operations. Net sales increased substantially to $2,996,530 from $1,077,743, although the company continues to carry a significant stockholders' deficit of over $23 million.
RMX Industries, Inc. reported a net loss of $19.4 million for the nine months ended September 30, 2026, compared to a $15.0 million loss in the prior year period, driven largely by $10.4 million in losses on warrant conversions. Revenue significantly declined to $3,722 from $311,344 year-over-year as the company pivoted its focus toward physical-edge intelligence and VAST technology.
Fabric.AI, Inc. reported a net loss of $19.8 million for the nine months ended September 30, 2026, compared to a $16.1 million loss in the prior year period. The company significantly increased its research and development spending to $10.2 million and ended the quarter with $39.2 million in total assets, largely driven by new issuances of Series J and K convertible preferred stock.
Newton Golf Company reported Q3 2026 net sales of $1.4 million, a decline from $2.6 million in the prior year due to marketing agency transitions and strategy changes. Despite lower revenue, the company improved its net loss to $1.2 million compared to $1.6 million in the prior-year quarter, driven by reduced operating expenses. Subsequent to the quarter-end, the company strengthened its balance sheet by raising approximately $3.0 million in net proceeds from equity financings.
Central Plains Bancshares, Inc. reported net income of $2.66 million for the six months ended September 30, 2026, an increase from $1.87 million in the prior year period. The growth was driven by higher net interest income, though the company experienced a significant increase in accumulated other comprehensive loss due to unrealized holding losses on available-for-sale securities.
TurnOnGreen, Inc. reported a net loss of $1.58 million for the nine months ended September 30, 2026, a slight improvement from the $1.70 million loss in the prior year. While revenue grew to $5.15 million, the company faces significant liquidity challenges with a $34.4 million shareholders' deficit and substantial doubt regarding its ability to continue as a going concern.
PEDEVCO reported Q3 2026 financial results, highlighted by a 411% year-over-year revenue increase to $35.5 million driven by production growth from its Rockies asset base. Despite higher operating income, the company reported a net loss of $9.2 million primarily due to a $16.6 million loss on derivative contracts. Management updated its full-year capital expenditure guidance to $37-$42 million to reflect accelerated development activity and lease acquisitions.
Annovis Bio reported a net loss of $41.9 million for the nine months ended September 30, 2026, compared to $19.0 million in the prior year, driven primarily by a significant increase in research and development expenses. The company's cash position decreased to $2.8 million from $19.5 million at the end of 2025, though it raised approximately $30.2 million through equity and warrant issuances during the period.
For the nine months ended September 30, 2026, FDCTech reported a significant revenue increase to $35.9 million compared to $17.3 million in the prior year, driven largely by its Brokerage (Trading) segment. Net income attributable to shareholders rose to $8.26 million, though the company experienced a net loss of $6.32 million in the third quarter of 2026 due to high costs of sales and operating expenses.
DSS, INC. reported a total revenue of $11.5 million for the nine months ended September 30, 2026, a decrease from $16.6 million in the prior year period. The company experienced a net loss of $16.3 million during this period, driven by higher operating costs and losses on investments, resulting in a total stockholders' equity of $4.3 million.
Microbot Medical Inc. reported a net loss of $15.14 million for the nine months ended September 30, 2026, compared to $9.68 million in the prior year, as the company began generating initial revenues of $418,000. Operating expenses increased significantly, particularly in sales and marketing, while cash and marketable securities decreased to approximately $61.8 million.
Peraso Inc. reported a significant decline in total net revenue to $0.3 million for the third quarter of 2026, down from $3.2 million in the prior year period, primarily due to lower product sales. The company's net loss widened to $2.7 million for the quarter, and cash reserves decreased to $0.6 million as of September 30, 2026, compared to $2.9 million at the end of 2025.
General Catalyst Global Resilience Merger Corp. is a blank check company that completed its IPO on May 1, 2026, raising $402.5 million. For the period from inception through September 30, 2026, the company reported net income of $5.17 million, primarily driven by $5.89 million in interest earned on cash held in the Trust Account, offset by $0.72 million in operating expenses.
Vuzix Corporation reported third quarter 2026 financial results, showing a 38% revenue decline to $0.7 million as the company transitions toward an OEM-focused business model. The company reported a net loss of $8.4 million ($0.10 per share) while highlighting progress in its defense business and the launch of its Causeway optical interconnect platform.
Term
Q3 2026
“During the third quarter, Vuzix continued to advance its transition towards a more OEM-focused business built around advanced waveguide technologies, optical engineering and its U.S.-based manufacturing capabilities.”
TRex Bio, Inc. is a clinical-stage biopharmaceutical company that has incurred substantial losses since inception and expects these losses to increase as it develops its autoimmune and inflammatory disease product candidates. As of November 5, 2026, the company had 28,788,654 shares of common stock outstanding and is classified as an emerging growth company.